• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Moderna Is a Breath of Fresh Air

I'm long this name, as I am several of the others involved. Will I add on a day like this?
By STEPHEN GUILFOYLE
May 18, 2020 | 10:12 AM EDT
Stocks quotes in this article: MRNA, PFE, JNJ, SNY

If it seems like I spend a lot of time covering the stocks of companies focusing on the war against Covid-19, I am. Like you, I know that not only the welfare of my portfolio, but any hope we all have in returning to an elevated quality of life truly depends on being able to either effectively treat, or completely avoid this disease all together. Not to avoid the disease through avoiding social contact, but to not worry about the guy walking the other way on the sidewalk, or the kid behind the counter at the convenience store. You want to go to a ballgame? A concert? The theater? Or just eat out? Don't we all.

Moderna (MRNA) is the firm behind one of the higher profile attempts to produce one of these "effective" vaccines, creating their mRNA-1273 candidate. This candidate is in the cutting edge of a new technology that has never been approved for actual use before... messenger RNA technology, which elicits an immune response through basically changing the instructions for the individual's body when exposed to potential infection. Moderna does their first human being with this product back on March 16th. Are we out of the woods? Of course not, but the very earliest results across a very small sample of participants are better than bad, in fact, these early results are as good as we could hope. A breath of fresh air.

This Is The Deal

In the Phase 1 (Phase 1 is really about safety, then we move on to efficacy.) clinical trial for mRNA-1273, Moderna does 45 volunteers aged 18 to 55, across three separate dosages. The plan was to dose one group at 25 micrograms twice, one group at 100 micrograms twice, and one group at 250 micrograms once. First off, the safety results were encouraging. The vaccine candidate appears to be well-tolerated. Three volunteers at the highest dosage developed Grade 3 systemic reactions. There were no life threatening reactions. There were no serious reactions at lower dosages.

What's interesting is that some data was released for the first eight individuals dosed. Four at the 25 microgram rate and four at 100. The interim Phase 1 data demonstrates that for the four dosed at the 25 microgram level, the vaccine elicits an immune response of the magnitude caused by having recovered from the natural infection, according to the firm's chief medical officer, Tal Zaks. Individuals that received the higher, but not maximum dosage showed binding antibody levels significantly exceeding the levels of those that have already survived the disease.

Moving Right Along

Now what? Even before all of the Phase 1 data is in, the FDA has already approved the start of Phase 2 trials for Moderna's mRNA-1273, and the firm plans to move forward with Phase 3 testing as soon as July. Compressed? Yes, the timeline is compressed. Yes, there is a sensed of urgency. Not just in beginning next phases ahead of early phase completion, but also in creating enough scale to manufacture hundreds of millions of doses. That's the president's "Operation Warp Speed" operation and it includes all of the various firms leading the way in developing a vaccine rapidly.

Beyond Moderna, big pharma is deep on this, including the likes of Pfizer (PFE) , Johnson & Johnson (JNJ) , and Sanofi (SNY) . Even the U.S. Army is involved in terms of providing necessary logistical support. The idea is to get the first safe and effective vaccine out to the masses. Broadly. By year's end. Even earlier for those on the medical front lines and first responders, if the administration has their way.

As for Moderna, the firm wold like to add a dosage of 50 micrograms to the Phase 2 trial, and amend the Phase 1 results to include these results.

The Chart

Obviously there is some muscle behind this Monday pop, but as readers will note, the shares ran into resistance in the early going as the upper trend line of our Pitchfork model (which I have shown you before). I am long this name, as I am several of the others involved. Will I add on a day like this? Truth is that I am more than likely to sell a little on such a day.

My current price target is $44, and that is up from where it was. Truth is that I am rooting for the human race, so I probably will not sell, but under any other conditions, with a stock trading close to twice my target, I would reduce, and reset. I will probably sell calls against the position. You can still get the May 22nd $90's for more than $3. That sounds like a deal.

(Johnson & Johnson is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells JNJ? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long MRNA, JNJ, PFE equity.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Coronavirus

More from Investing

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login